NCT02675803View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 20, 2010

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

VAY736

VAY736 treatment

BIOLOGICAL

VAY736 placebo

VAY736 placebo

Trial Locations (1)

10117

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY